| Abstract: | Polycystic ovary syndrome (PCOS) appears to be the most common endocrine disorders of women. It is associated with significant reproductive, endocrine, metabolic, and cardiovascular morbidity. Hyperinsulinemia and insulin resistance, which result in hyperandrogenemia have been documented as a central role in the pathogenesis of PCOS. Treatment with insulin sensitizer, metformin, has been shown to follow by regularization of menstrual cycle, improved response to ovulation induction and reduction of hyperandrogenism. It possibly prevents early trimester pregnancy loss and decrease the risk of developing type Ⅱ diabetes and cardiovascular disease. This article aims to review the current evidence on the use of metformin in women with PCOS. |
